FDA-approved therapies for chronic GVHD

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Chronic graft-versus-host disease (cGVHD) is a significant complication after allogeneic hematopoietic cell transplantation.
• cGVHD impacts multiple organs, diminishes quality of life, and poses treatment challenges due to adverse effects.

Purpose of the Study:

• To review recent US Food and Drug Administration (FDA)-approved therapies for cGVHD.
• To discuss the targeted signaling pathways and cell types for these novel treatments.
• To outline future research directions in cGVHD clinical studies.

Main Methods:

• Review of clinical studies supporting FDA approval of new cGVHD drugs.
• Analysis of targeted mechanisms of action for ibrutinib, ruxolitinib, belumosudil, and axatilimab.
• Discussion of current and future clinical research in cGVHD.

Main Results:

• Four drugs (ibrutinib, ruxolitinib, belumosudil, axatilimab) approved by the FDA in the past decade for cGVHD.
• These therapies target specific molecular pathways and cellular interactions implicated in cGVHD pathogenesis.
• Clinical trials formed the basis for these approvals, demonstrating efficacy and safety profiles.

Conclusions:

• Recent therapeutic advancements have provided new options for managing cGVHD.
• Understanding targeted pathways and cell types is crucial for optimizing treatment strategies.
• Continued clinical research is essential to further improve outcomes for patients with cGVHD.